

FOR IMMEDIATE RELEASE



NEW DATA ON QUANTIFICATION OF 379 PROTEINS DIRECTLY FROM A SINGLE MASS SPECTROMETRY RUN ON BLOOD EXTRACTED FROM DRY PLASMA SPOT CARDS ADVANCES FUTURE OF HEALTHCARE

Applied Proteomics to Present Advances in Technology at the American Society of Mass Spectrometry 2017 Annual Meeting

SAN DIEGO, Calif., May 30, 2017 – [Applied Proteomics, Inc.](#) (API), an innovation technology company that leverages the power of the proteome for monitoring health and early detection of disease, today announced that it will be presenting new data utilizing its Linus™ technology—the world’s most advanced and robust protein discovery and commercial development platform. Linus’ unmatched reproducibility, accuracy, and efficiency make it the only mass spectrometry platform that can deliver the promise of developing the body’s “check engine light.” These data will be presented in poster sessions at the American Society of Mass Spectrometry (ASMS) 2017 Annual Meeting in Indianapolis, IN (June 4-8, 2017).

“Our Linus technology continues to demonstrate its ability to detect and identify proteins with unparalleled reproducibility, combined with high accuracy and efficiency,” said Premal Shah, PhD, CEO of Applied Proteomics, Inc. “This never-before-seen power will enable us to deliver low-cost, clinical-grade products that will finally harness the power of proteins—from a single finger prick—to fill a vast unmet need in healthcare: the body’s check engine light.”

The work presented at the ASMS meeting advances the field in significant ways: The ability to quantify over 800 peptides (~380 proteins) utilizing SIS peptides in a single LCMS injection directly from dried plasma spot card samples with clinical-grade reproducibility and accuracy. “The gold standard for quantitation of proteins with LCMS is through the utilization of internal standards (e.g. SIS peptides) with QQQ instruments, however there is an upper boundary of how many proteins can be multiplexed. Here, we present a novel method for potentially unlimited multiplexing of quantitative protein assays with high resolution and mass accuracy instrumentation. Perhaps more impressively, we have demonstrated the novel method on a low-cost, easy to use sample collection format (DPS cards) that further addresses sample acquisition challenges.” said Bruce Wilcox, Ph.D., Senior Vice President of R&D.

- Continued -

In a separate poster, API continues to develop its blood-based test for colorectal cancer (CRC) in patients with elevated risk. A new multiplexed quantitative assay of 392 proteins associated with CRC was applied to more than 1,000 patients in one of the largest studies ever completed. “In the elevated-risk population, CRC symptoms do not always result in high compliance with colonoscopy, the gold standard. Our cost-effective test provides physicians with more valuable information for their colonoscopy recalcitrant patients,” said Shah. Wilcox added, “the development of this assay proves the power of Linus: integrating rigorous QC of the entire workflow along with tight control of the mass spectrometry, enables reproducible analysis of hundreds of proteins on >1,000 patient samples spanning weeks or months. High quality datasets, such as this one, allow us to then apply machine-learning techniques to identify the optimal biomarker signature.”

Details of the poster viewings are as follows:

Title: *A Synergistic Approach: Combining Label-Free Proteomics and MRM Techniques in a Single Method to Advance Healthcare*

Date/time: Monday, June 5, 10:30 a.m. – 2:30 p.m.

Poster Number: MP 623

Title: *Development of a Mass Spectrometry-Based Targeted Quantitative Assay for Use in the Identification of a Colorectal Cancer Peptide Signature*

Date/time: Monday, June 5, 10:30 a.m. – 2:30 p.m.

Poster Number: MP 043

Applied Proteomics’ CEO and the SVP of R&D will be available for one-on-one meetings at the scientific meeting. To schedule a meeting or speak with them in advance of the meeting, please contact Ramune Carothers at rcarothers@appliedproteomics.com or at 949-542-9698.

About Applied Proteomics Inc.

Applied Proteomics Inc. develops noninvasive, blood-based tests that leverage the power of the proteome—the body’s complete system of proteins—for monitoring and early detection of disease. Our proprietary Linus technology, a protein discovery and test delivery engine, is focused on isolating relevant signals associated with increased risk of disease in a rapid and cost-effective manner to develop highly sensitive and specific diagnostic tests.

###

CONTACT:

Ramuné Carothers

Director of Marketing, Applied Proteomics, Inc.

949-542-9698

rcarothers@appliedproteomics.com

www.appliedproteomics.com